For the Inventor, By the Inventor

Enter assignee name

Marlborough, MA, United States of America

Sepracor, Inc.

Calculating rank

USPTO Granted Patents = 322

% Expired Patents = 13.7

CIPO Patents = 20

EPO Patents = 8

Trademarks = 6

Forward Citations = 4,244

Loading Chart...

Loading Chart...

126 inventors (with patents filed for the assignee):

James W Young (47 out of 50 patents)

Thomas P Jerussi (40 out of 53 patents)

Chris Hugh Senanayake (33 out of 77 patents)

4. Paul D Rubin (33 out of 36 patents)

5. James R Hauske (32 out of 32 patents)

6. John R McCullough (32 out of 32 patents)

7. Timothy J Barberich (30 out of 32 patents)

8. Qun Kevin Fang (24 out of 37 patents)

9. Gregory D Cuny (24 out of 69 patents)

10. Charles M Zepp (23 out of 57 patents)

11. Yun Gao (20 out of 40 patents)

12. Nancy M Gray (20 out of 21 patents)

13. Brian M Aquila (19 out of 29 patents)

14. Chrisantha Hugh Senanayake (19 out of 24 patents)

15. William E Yelle (18 out of 18 patents)

Core Competencies:

CNS Disorders

D-Amino Acid Oxidase

Piperidine Ligands

Anxiolytics

Migraine Treatment

Pulmonary Disorders

Stereoselective Synthesis

Pain Management

Neurotransmitter Receptors

Heterocyclic Compounds

Optically Active Derivatives

Sibutramine Metabolites

322 patents: Sort by Forward Citations

1. 7902252 - Inhibitors of D-amino acid oxidase (2011-03-08),

2. 7893098 - Pyrrole and pyrazole DAAO inhibitors (2011-02-22),

3. 7884124 - Fluoro-substituted inhibitors of D-amino acid oxidase (2011-02-08),

4. 7816375 - Ligands for monoamine receptors and transporters, and methods of use thereof (2010-10-19),

5. 7812035 - 4-substituted piperidines, and methods of use thereof (2010-10-12),

6. 7790772 - [object Object] (2010-09-07),

7. 7776858 - Methods of treatment of chronic pain using eszopiclone (2010-08-17),

8. 7732641 - Formoterol tartrate process and polymorph (2010-06-08),

9. 7723324 - Imidazo[1,2-A]pyridine anxiolytics (2010-05-25),

10. 7718822 - Carbamate Stereoisomer (2010-05-18),

11. 7714023 - Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites (2010-05-11),

12. 7692019 - Methods for the stereoselective synthesis of substituted piperidines (2010-04-06),

13. 7671087 - Amines that inhibit a mammalian anandamide transporter, and methods of use thereof (2010-03-02),

14. 7615572 - Pyrrole and pyrazole DAAO inhibitors (2009-11-10),

15. 7589237 - Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine (2009-09-15),

Company Overview

Sepracor, Inc., based in Marlborough, MA, specializes in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company focuses on advanced technologies related to D-Amino Acid Oxidase and piperidine ligands, targeting conditions such as anxiety, migraines, and pulmonary disorders. Sepracor is dedicated to enhancing pain management solutions through its expertise in stereoselective synthesis, contributing to improved patient outcomes in the field of CNS health.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

322 Patents

#5 in Marlborough, MA

#77 in Massachusetts

#1,371 in US

#2,800 in the World

Marlborough, MA, United States of America

Sepracor, Inc.

Forward Citations = 4,244

126 inventors:

James W Young (47 out of 50 patents)

Thomas P Jerussi (40 out of 53 patents)

Chris Hugh Senanayake (33 out of 77 patents)

4. Paul D Rubin (33 out of 36 patents)

5. James R Hauske (32 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sepracor, Inc.. Retrieved from https://idiyas.com/company/sepracor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…